Filing Flows › Cytosorbents (CTSO) › Q2 2026 › vs Q1 2026
Cytosorbents (CTSO) Q2 2026 vs Q1 2026 (quarter over quarter)
Cytosorbents's revenue rose $769K (+9%) from $8.9M in Q1 2026 to $9.6M in Q2 2026.
Cytosorbents, Q2 2026: revenue $9.6M (+0.2% year over year), operating margin -27.4%, net loss $4.4M, operating cash flow −$583K. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $9.6M | $8.9M | $769K | +9% |
| Net loss | $4.4M | $5.1M | −$711K | -14% |
| Costs & expenses | $14.1M | $14.0M | $58K | +0.4% |
| Operating costs | $12.3M | $11.9M | $363K | +3% |
| Interest & other, net | $1.8M | $2.1M | −$305K | -15% |
| Cost of revenue | $2.6M | $2.7M | −$150K | -5% |
| Research & development | $1.5M | $1.0M | $428K | +42% |
| SG&A | $8.0M | $8.1M | −$185K | -2% |
| Operating cash sources | $4.4M | $5.1M | −$711K | -14% |
| Depreciation & amortization | $360K | $350K | $10K | +3% |
| Share-based compensation | $368K | $544K | −$176K | -32% |
| Working capital & other | $3.1M | $3.1M | $34K | +1% |
| Cash used in operations | $583K | $1.2M | −$579K | -50% |
| Net loss absorbed | $4.4M | $5.1M | −$711K | -14% |
Questions
How much did Cytosorbents's revenue grow quarter over quarter in Q2 2026?
Cytosorbents's revenue rose $769K (+9%) from $8.9M in Q1 2026 to $9.6M in Q2 2026.